ABSTRACT
Aim: This meta-analysis was performed to assess the efficacy and safety of mavacamten in patients with hypertrophic cardiomyopathy. Methods & materials: A search was conducted using PubMed, Cochrane, and Scopus up to August 2022 for randomized studies reporting our pre-specified outcomes. Results: It was observed that mavacamten significantly improved New York Heart Association class (p < 0.009), Clinical Summary Score of the Kansas City Cardiomyopathy Questionnaire (p = 0.02), post-exercise left ventricular outflow tract gradient (p < 0.00001), functional end point (p = 0.05), and lowered septal reduction therapy rates (p < 0.00001). However, there were no significant differences in the ≥1 severe adverse events, ≥1 treatment-emergent adverse events, left ventricular volume index, left ventricular filling pressure, left ventricular end-diastolic volume index, and peak oxygen uptake (pVO2). Conclusion: Future large-scale trials are required to confirm our results and determine the long-term benefits and risks of mavacamten use in these patients.
Mavacamten is a recently introduced medication that relaxes the heart muscle and is indicated for patients with hypertrophic cardiomyopathy (a disease in which parts of the heart become thick and stiff). To determine the effectiveness and safety of this drug, the results of clinical trials were combined in order to produce an overall estimate. Overall, it was observed that mavacamten improved most functional parameters related to the heart and demonstrated no significant increases in the number of side effects. This suggests the effectiveness and safety of mavacamten, although further trials are needed to confirm our results.
ABSTRACT
The re-emergence of polio in the UK reminds us that the global threat of polio remains. Viruses know no bounds or borders. COVID-19, Monkeypox, and polio are evidence of this. Poliomyelitis was once the leading cause of death and paralysis in the UK and globally. With the introduction of vaccines during the 1950s-1960s, polio was eradicated from most developed countries, including the UK. The last case of wild polio was in 1984, and the UK was polio-free in 2003. The recent detection of vaccine-derived poliovirus type 2 in London sewage samples is alarming. Routine inoculations were adversely affected due to COVID-19, and UK's wastewater monitoring program was suspended due to economic restrictions. The UK faces several challenges with the burden of COVID-19, Monkeypox, and the return of polio could further burden the already pandemic-stricken healthcare system. To prevent further epidemics in the UK, wastewater sampling remains crucial in evaluating, searching, and eradicating the spread of poliovirus. Further epidemiological surveillance in adjacent areas to the Beckton plant is crucial to filling any gaps in understanding the outbreak's extent and guiding the initiation of appropriate and timely public health measures. The importance of vaccination in unvaccinated or incompletely vaccinated individuals cannot be overstated, especially in areas where vaccination rates are low. The risk of polio remains globally until its complete eradication from endemic countries. Until elimination, a global effort should be made to minimize the risk and the consequent spread of poliovirus by maintaining strong population immunity levels through high vaccination coverage.
